Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Duke University Novartis |
---|---|
Information provided by: | Duke University |
ClinicalTrials.gov Identifier: | NCT00286871 |
Liver transplant subjects will be given Mycophenolate (MMF) and Tacrolimus in order to help prevent post-transplant rejection.
Condition | Intervention | Phase |
---|---|---|
Chronic Hepatitis C Organ Transplantation Immunosuppression |
Drug: Neoral Drug: Tacrolimus |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Steroid Avoidance in Hep C OLT |
Estimated Enrollment: | 40 |
Study Start Date: | February 2006 |
Estimated Study Completion Date: | February 2009 |
Recurrent HCV in the liver allograft is becoming the leading indicator for retransplantation. Studies suggest that glucocorticord-based immunosuppression regimens hasten the onset and progression of recurrent chronic HCV liver disease. Treatment of acute allograft rejection with steroid boluses is also associated with rapid HCV recurrence. The relative contribution of various calcineurin inhibitors to recurrent HCV liver disease has not been established. Previous retrospective studies, as well as prospective studies have not demonstrated a difference in recurrent HCV liver disease rates between patients receiving CsA or tacrolimus immunosuppression regimens respectively.
Ages Eligible for Study: | 18 Years to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, North Carolina | |
Duke University Medical Center | |
Durham, North Carolina, United States, 27710 |
Principal Investigator: | Devai Desai, MD, PhD | Duke University |
Study ID Numbers: | 6538-04-11R0 |
Study First Received: | February 2, 2006 |
Last Updated: | February 2, 2006 |
ClinicalTrials.gov Identifier: | NCT00286871 History of Changes |
Health Authority: | United States: Institutional Review Board |
Liver Diseases Cyclosporine Hepatitis, Chronic Immunologic Factors Hepatitis, Viral, Human Tacrolimus Cyclosporins |
Immunosuppressive Agents Hepatitis Virus Diseases Digestive System Diseases Hepatitis C Hepatitis C, Chronic |
Liver Diseases RNA Virus Infections Hepatitis, Chronic Flaviviridae Infections Immunologic Factors Physiological Effects of Drugs Hepatitis, Viral, Human Tacrolimus |
Immunosuppressive Agents Pharmacologic Actions Hepatitis Virus Diseases Digestive System Diseases Hepatitis C Hepatitis C, Chronic |